1. Home
  2. PTY vs AGIO Comparison

PTY vs AGIO Comparison

Compare PTY & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Opportunity Fund

PTY

Pimco Corporate & Income Opportunity Fund

HOLD

Current Price

$11.69

Market Cap

2.6B

Sector

Finance

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$36.36

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTY
AGIO
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2002
2013

Fundamental Metrics

Financial Performance
Metric
PTY
AGIO
Price
$11.69
$36.36
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$38.88
AVG Volume (30 Days)
1.0M
1.1M
Earning Date
01-01-0001
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$76.75
Revenue Next Year
N/A
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.58
$22.24
52 Week High
$14.69
$46.00

Technical Indicators

Market Signals
Indicator
PTY
AGIO
Relative Strength Index (RSI) 38.30 47.03
Support Level $11.62 $26.71
Resistance Level $11.98 $44.51
Average True Range (ATR) 0.09 1.85
MACD -0.04 -0.87
Stochastic Oscillator 18.18 13.39

Price Performance

Historical Comparison
PTY
AGIO

About PTY Pimco Corporate & Income Opportunity Fund

PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: